The US patent US9035074 for abrocitinib, titled "ABROCITINIB CRYSTAL FORMS," was filed by Pfizer Inc. [1]. This patent specifically claims crystalline forms of abrocitinib, which are important for drug formulation and stability [1].
When does the abrocitinib patent expire?
The expiration of US patent US9035074 for abrocitinib is a key factor in determining when generic versions of the drug could become available. Patents typically last for 20 years from the filing date, but extensions can be granted. Information on the exact expiration date and any potential extensions for this specific patent can be found through patent tracking services [2].
What does US9035074 patent cover?
US patent US9035074 covers specific crystalline forms of abrocitinib. These crystalline forms are crucial for the manufacturing process, as they can affect a drug's bioavailability, stability, and ease of formulation into a finished dosage form [1]. The claims in this patent define the precise chemical structures and properties of these abrocitinib crystal forms that Pfizer Inc. has exclusive rights to [1].
How does abrocitinib work and what is it used for?
Abrocitinib is a Janus kinase (JAK) 1 inhibitor. It works by blocking the activity of a specific enzyme, JAK1, which plays a role in the immune system's inflammatory response [3]. By inhibiting JAK1, abrocitinib reduces inflammation associated with certain autoimmune conditions. It is approved for the treatment of moderate to severe atopic dermatitis (eczema) in adults and adolescents [3].
Who makes abrocitinib?
Abrocitinib is developed and manufactured by Pfizer Inc. [1, 3]. It is marketed under the brand name Cibinqo [3].
What are the potential risks or side effects of abrocitinib?
Like many medications, abrocitinib carries potential risks and side effects. Common side effects can include upper respiratory tract infections, nausea, headache, and acne [3]. More serious risks, which are often highlighted in drug labels and patient information, include the potential for serious infections, blood clots, cardiovascular events, and certain types of cancer [3]. Patients are advised to discuss these risks thoroughly with their healthcare providers [3].
Can generic abrocitinib be made before patent expiry?
Generally, generic versions of a drug cannot be manufactured or marketed before the relevant patents expire or are successfully challenged. Pharmaceutical companies that develop new drugs invest heavily in research and development, and patents provide a period of market exclusivity to recoup these investments. Companies can challenge patents, but this is a complex legal process. Biosimilar or generic manufacturers will typically wait for patent expiry or a successful legal outcome before launching their products to avoid patent infringement [2].
Sources:
[1] https://patents.google.com/patent/US9035074B2/
[2] https://drugpatentwatch.com/
[3] https://www.cibinqo.com/